DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know

DaVita HealthCare (DVA) shares rose 1.26% in recent trading, outperforming the S&P 500, and analysts anticipate a 4.25% EPS increase to $2.7 in the upcoming earnings report with revenue expected to reach $3.3 billion, a 3.5% increase year-over-year. Full-year estimates project an 11.16% EPS increase to $10.76 and a 5.15% revenue increase to $13.48 billion. The stock currently has a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 12.66, a discount compared to its industry's average of 20.85.

Analysis

DaVita HealthCare (DVA) recently posted a 1.26% daily stock price increase to $137.84, outperforming the S&P 500's 0.94% gain, though its shares have declined 6.39% over the past month, lagging both the Medical sector's 4.95% gain and the S&P 500's 1.67% rise. Forthcoming earnings are a key focus, with analysts anticipating a 4.25% year-over-year rise in EPS to $2.70 and a 3.5% increase in revenue to $3.3 billion for the quarter. Full-year projections suggest stronger growth, with an expected 11.16% increase in EPS to $10.76 and a 5.15% rise in revenue to $13.48 billion. Despite the positive growth outlook and generally favorable implications of upward analyst revisions, the Zacks Consensus EPS estimate for DVA has remained stagnant over the last month, contributing to its current Zacks Rank of #3 (Hold). Valuation metrics appear favorable, with a Forward P/E ratio of 12.66, a discount to its industry's average of 20.85, and a PEG ratio of 0.94, which is considerably lower than the industry average of 1.93. The company's Medical - Outpatient and Home Healthcare industry is ranked in the top 29% by Zacks.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings report for validation of the projected EPS growth of 4.25% and revenue increase of 3.5%, as this will be pivotal in reassessing the stock's trajectory given its recent monthly underperformance.
• The current Zacks Rank of #3 (Hold) and stagnant consensus EPS estimates over the past month warrant a cautious approach, despite attractive valuation metrics like a Forward P/E of 12.66 and a PEG ratio of 0.94.
• A confirmed strong earnings performance and any subsequent positive revisions to analyst estimates could signal a buying opportunity, especially if the company reiterates or improves upon its robust full-year growth projections of 11.16% for EPS and 5.15% for revenue.